Who This Is For
Laboratory directors
Medical directors
Pathologists and clinical reviewers
Quality leaders
LIS and informatics teams
CTOs
at CLIA-certified, CAP-accredited, and ISO 15189-accredited laboratories evaluating AI that drafts or supports test interpretation.
Why This Matters
A vendor demo can show an AI drafting a clean interpretive comment and still say nothing about how it behaves in your lab.
Local evidence matters when your lab uses its own reference intervals, issues corrected results, depends on LIS mappings, or relies on a reviewer to approve every draft. Under CLIA, a lab must verify that a manufacturer's reference intervals suit its own patient population before reporting results (42 CFR 493.1253(b)(1)(ii)). CAP also expects the laboratory director to ensure AI and machine learning algorithms are validated or verified before patient testing.
This workbook helps your team build that evidence one workflow at a time, before the AI influences a single patient report.
- Define exactly what the AI may and may not do, including excluded uses and missing-data behavior.
- Test whether qualified reviewers actually catch a wrong reference interval, an unsupported recommendation, or incorrect patient linkage.
- Record a release decision, monitoring plan, and change process your laboratory director can review and sign.
What's Inside
The workbook walks your team through the controls behind a safe AI-assisted interpretation workflow:
Intended use and workflow boundaries
Evaluated configuration:
model release, prompts, knowledge sources, LIS mappings, and report template
Case selection and reference standards
Acceptance criteria approved before results are reviewed
Qualified human review testing
Shadow evaluation alongside your current process
Release decision and evidence index
Production monitoring and error investigation
Change assessment and retesting after model or vendor updates
What You'll Walk Away With
Fill-in worksheets and log templates for input contracts, case records, review logs, execution logs, incidents, and changes.
Fictional worked examples that show the level of detail needed, with no patient data.
A clearer basis for deciding whether your next priority is case selection, reviewer testing, LIS integration, version control, or production monitoring.
References to 42 CFR 493.1253, FDA's Clinical Decision Support Software guidance, and ADLM's July 2026 AI policy report.
